Chromogranin A is a PAM substrate and a strong candidate for mediating downstream effects on insulin secretion. Taken together, our results establish a role for PAM in beta cell function, and uncover a novel mechanism for T2D-associated PAM alleles.
INTRODUCTION
Human genetics has the potential to identify novel mechanisms for disease, which in turn present opportunities for clinical translation. Over the past 10 years, genome-wide association studies (GWAS) have identified over 150 genomic regions robustly associated with type 2 diabetes (T2D) risk, and have revealed a central role for pancreatic beta cell dysfunction in T2D pathogenesis (1) (2) (3) . However, the translation of GWAS signals into molecular mechanisms for disease has been slow, primarily due to uncertainty over the transcripts through which non-coding association signals operate (4) . Recently, studies focused on identifying coding variant association signals have identified nonsynonymous alleles in Peptidylglycine Alpha-amidating Monooxygenase (PAM) independently associated with T2D risk (rs78408340, p.S539W; and rs35658696, p.D563G), providing a direct link to the effector transcript (3, 5) . The T2D risk alleles are also associated with reduced insulinogenic index -a measure of glucose-stimulated insulin secretion -suggesting that their effects are mediated via altered beta cell function (5) (6) (7) .
PAM encodes peptidylglycine alpha-amidating monooxygenase (PAM), an enzyme in neuroendocrine cells that modifies peptides with a C-terminal glycine to create peptideamides (8) (9) (10) . Amidation can dramatically increase the biological potency of a peptide relative to its unmodified glycine-extended conjugate (11) . PAM is localised to the Golgi, where it is packaged with other endocrine proteins into nascent granules (8, 12) . The functional enzyme exists in both integral membrane and luminal forms, the latter of which is co-secreted with the endocrine peptide(s) (8, 10, 13) .
Despite reports of PAM expression in pancreatic islets, a functional role in beta cells has not yet been described (14) . Insulin itself is not a PAM substrate, so the effects of PAM on beta cell function are therefore mediated by other peptide(s). We hypothesised that T2D-associated PAM missense alleles reduce PAM function, affecting amidation of peptides critical for insulin secretion. We demonstrate that both diabetes risk alleles negatively impact on PAM expression and/or activity, and elucidate an endogenous role for PAM in insulin granule packaging and release from beta cells. We also show that PAM amidates the granule packaging factor Chromogranin A (CgA), and establish this neuroendocrine peptide as a likely downstream effector of PAM in beta cells. Our results are consistent with the direction and magnitude of effects for T2D-associated risk alleles in PAM, and establish molecular mechanisms for their impact on disease susceptibility.
RESULTS

T2D-associated PAM alleles cause PAM loss-of-function
PAM is a bifunctional enzyme, possessing two contiguous catalytic domains: peptidylglycine alpha-hydroxylating monooxygenase (PHM), and peptidyl alpha-hydroxyglycine alphaamidating lyase (PAL) (10) . The p.S539W and p.D563G missense mutations are both located within the PAL domain and are predicted by in silico tools (SIFT, PolyPhen2) to be damaging, suggesting that they could affect enzymatic activity. To test this, we generated Human Embryonic Kidney (HEK) 293 cell lines expressing recombinant secreted (nonintegral membrane) PAM protein for in vitro amidation assays. In line with previous observations, PAM was constitutively released into supernatant (Supplementary Figure 1A) (15). WT-PAM and D563G-PAM were robustly produced, as well as an additional catalytically inactive mutant protein, Y651F-PAM, which was used as a control (16) .
Interestingly, we were unable to detect S539W-PAM expression (Supplementary Figure 1A) . This was observed across three independently derived cell lines, and was not due to cellular retention of S539W-PAM (data not shown).
We subsequently developed a cell-free kinetic assay capable of measuring PAM amidating activity via spectrophotometric detection of converted glyoxylate, a by-product of the amidation reaction (17, 18) . Matching each reaction for PAM input, we observed reduced amidating activity for D563G-PAM (p=1.0x10 -5 ) and Y651F-PAM (p=4.1x10 -6 ) ( Figure 1A ).
In agreement with its lack of expression, supernatant from S539W-PAM-transfected cells was inactive in this assay (Supplementary Figure 1B) . Further analysis showed no significant difference in substrate affinity between WT-PAM and D563G-PAM (K m 0.95mmol/L vs 1.02mmol/L, p=0.44), suggesting that the p.D563G substitution affects K cat (Supplementary Figure 1C ). These results demonstrate that the T2D-associated PAM coding alleles decrease PAM function via a combination of defective expression and/or reduced catalysis.
PAM localises to the beta cell secretory pathway
Having established the direction of effect for T2D risk alleles in PAM, we next explored a role for PAM in physiologically relevant tissues. Transcript expression profiling detected PAM in multiple tissue types, with highest expression in human islets ( Figure 1B and Supplementary Figure 2Ai ). This is consistent with the published association between PAM risk alleles and reduced measures of insulin secretion, and suggests a direct role for PAM in beta cell function. We confirmed broadly similar expression patterns in the publicly available Genotype-Tissue Expression (GTEx) database, though data for pancreatic islets are not available from this project (19) . Published RNA sequencing data also showed PAM to be equally expressed in enriched fractions of beta cells and non-beta cells (Supplementary Figure 2Aii) (20, 21) . We verified this expression pattern at the protein level by immunofluorescent staining of human islets, which revealed co-localisation of endogenous PAM with insulin and glucagon ( Figure 1C ).
Detailed analysis of the subcellular localisation of WT and variant PAM proteins was then performed for both integral and secreted forms in the human beta cell line EndoC-βH1 (22) .
Integral membrane WT-PAM immunofluorescence localised to the trans-Golgi network (TGN), where secretory granules originate, whereas secreted WT-PAM displayed a punctate staining pattern and co-localised with endogenous insulin ( Figure 1D ). Similar results were observed for D563G-PAM and Y651F-PAM ( Supplementary Figure 2Bi -ii). As in HEK cells, secreted S539W-PAM expression was undetectable ( Figure 1Dii) ; however, integral membrane S539W-PAM displayed an aberrant staining pattern that localised to the endoplasmic reticulum (ER) as well as the TGN (Figure 1Di and Supplementary Figure 2Biii ). These results confirm that PAM localises to components of the beta cell secretory pathway, in agreement with studies in other neuroendocrine cell types (8, 12, (23) (24) (25) . The S539W substitution may interfere with PAM protein folding such that its translocation from the ER to the TGN is prevented or delayed.
PAM regulates glucose-responsive insulin secretion
Given the negative impact of both T2D risk alleles on overall PAM function, we next determined the effects of reduced PAM levels on beta cell activity. siRNA-mediated knockdown of PAM in EndoC-βH1 cells caused a 79% reduction in PAM transcript levels (Supplementary Figure 3A) , and decreased insulin secretion under both basal (-6.9%, p=0.04) and high glucose conditions (-14.4%, p=8. Figure 3B) . In contrast, the kinetics of vesicle release were significantly different; in controls cells, nearly 60% of the exocytotic response was elicited by the first pulse, compared with less than 40% in PAM knockdown cells (p=0.013) ( Figure 2F ). The increase in cell capacitance during the first two depolarizations provides an estimate for the size of the readily releasable pool (RRP) of secretory granules, and subsequent pulses represent mobilization of granules from the more intracellular reserve pool (RP) (26) . Our results indicate that PAM is an endogenous regulator of insulin availability and the exocytotic response in pancreatic beta cells, with a specific effect on the availability of the RRP.
Effects of PAM variants on primary beta cell function
Having established a role for PAM in a human beta cell model, we sought to corroborate our results by examining effects for the common PAM variant (rs35658696) on primary beta cell function. We analysed exocytosis in single beta cells from dispersed human islets, with capacitance measurements following a train of 10 depolarisations in either 1 or 10 mM glucose. Seven individuals heterozygous for the T2D risk allele were compared to seven age-, gender-, and BMI-matched individuals homozygous for the reference (non-risk) allele ( Figure 4A ). To specifically test for differences in the RRP, we calculated the total increase in capacitance during the first two depolarisations ( Figure 4B ). Although no differences were detected at low glucose, a significant decrease in capacitance was seen in risk allele carriers at 10 mM glucose (-26.5%; p = 0.04), indicative of reduced exocytosis from the RRP. Our results are therefore consistent with an effect of rs35658696 status on the kinetics of granule release that manifests predominantly under stimulated conditions.
Chromogranin A is a substrate and downstream effector of PAM in beta cells
To elucidate the PAM-regulated pathway in beta cells, we finally sought to identify plausible target proteins that could act as downstream effectors of PAM activity. While any C-terminal glycine-extended peptide could be a substrate for PAM, we reasoned that a key downstream mediator of the observed effects in beta cells would need to be co-expressed with PAM along the secretory pathway. We therefore searched a published catalogue of the islet secretome for potential targets of PAM amidation (27) . This highlighted two proteins, Chromogranin A (CgA, encoded by CHGA) and Islet Amyloid Polypeptide (IAPP, encoded by IAPP), both of which are highly expressed in beta cells and have plausible links with PAM function (27) .
CgA is a granular packaging protein that self-aggregates to condense large numbers of neuroendocrine peptides into nascent secretory granules (28) (29) (30) . It can also be cleaved to produce smaller peptides with additional biological roles (31) . The role of IAPP in beta cells is less well understood, although deposition of elongated fibrils in islets due to IAPP aggregation is a feature of T2D (32) . Figure 3C Figure 5D and Supplementary Figure 3D ) (33, 34 ). An antibody that recognises all forms of CgA (irrespective of amidation status) detected an additional lower molecular weight (~70kDa) form of CgA, presumably due to cleavage near its C-terminus.
CHGA silencing (Supplementary
Production of this cleaved form was altered in response to decreased PAM expression and activity, suggesting that processing of CgA may be regulated by PAM-dependent amidation ( Figure 4D ). These results confirm that CgA is a PAM substrate in beta cells, and a strong candidate for mediating the effects of PAM on beta cell function. In contrast, silencing of IAPP in EndoC-βH1 cells had no effect on insulin content or secretion (Supplementary Figure 3E-H) .
DISCUSSION
Recent efforts to catalogue coding variants associated with T2D risk have identified independent association signals in the PAM gene. The coding risk alleles are also associated with decreased insulinogenic index, a physiological measure of insulin secretion in response to a glucose challenge, indicating a likely endogenous role for PAM in beta cell function.
Here, we provide evidence that both T2D-risk alleles reduce overall PAM activity. We also show that reduced PAM expression causes beta cell dysfunction through multiple effects on insulin availability, secretion, and the dynamics of granule exocytosis. Importantly, these defects preferentially affect insulin secretion under stimulated conditions, leading to a blunted glucose response. In line with these results, we observed a consistent effect of the rs35658696 however, it appears generally to be more predominant in neuroendocrine cell types (15) . This raises the intriguing possibility of tissue-specific haploinsufficiency in p.S539W PAM carriers.
To explore the molecular mechanism underlying beta cell dysfunction in PAM risk allele carriers, we performed detailed characterisations of the human beta cell line EndoC-βH1
following PAM knockdown. The observed defects were broadly similar to those seen in primary human beta cells, with differential effects under stimulated conditions and a significant reduction in the size of the RRP. Interestingly, the effects of reduced PAM function under low glucose conditions in EndoC-βH1 cells were not apparent in primary beta cells. This may reflect differences in the degree of PAM loss-of-function between siRNAtreated EndoC-βH1 cells and rs35658696 risk allele carriers (as suggested by our in vitro assay), as well as methodological differences in pre-incubation time prior to capacitance measurements, which could affect the extent of granule repletion.
Our molecular studies in EndoC-βH1 cells confirm that CgA is a substrate for PAM amidation in beta cells (34) . CgA is a granular packaging protein known to influence vesicle composition in other neuroendocrine cell types by facilitating the condensation of secreted proteins within nascent secretory vesicles (28) (29) (30) (35) (36) (37) . Previous studies using global Chga knockout mouse models have attempted to investigate a role for CgA in pancreatic islets, but have been confounded by compensatory increases in other granin proteins including Chromogranin B (CgB) (38, 39) . Our results suggest a mechanism whereby amidation of
CgA by PAM enhances its ability to aggregate and package insulin efficiently in granules. In support of this hypothesis, amidation of numerous biological peptides has been shown to promote protein structure and self-aggregation due to improved electrostatic interactions (40) (41) (42) . C-terminal cleavage of CgA has also been found to increase protein stability in pituitary cells, and the C-terminal domain of PAM interacts with proteins that influence actin cytoskeleton remodelling in yeast-2-hybrid analyses (43) (44) (45) . These findings provide insights into the mechanism by which PAM and CgA may influence granule biogenesis.
Although our tissue expression analyses showed PAM to be most highly expressed in pancreatic islets, they also reveal that PAM is widely expressed in human tissues. It is therefore possible that PAM could influence beta cell function via amidated signals released from other cell types (21, 46) . Glucagon-like peptide 1 (GLP-1) is an amidated peptide released from intestinal L-cells in response to a meal that amplifies insulin secretion (47) .
Moreover, GLP-1 (7-36-amide) has an increased half-life compared to GLP-1 in vitro (7-37),
suggesting that amidation improves GLP-1 stability (48) . PAM may therefore have paracrine and endocrine effects on beta cell function via decreased GLP-1 amidation and/or secretion, which has implications for genotype-specific responses to incretin-based therapies.
In conclusion, we show that the amidating enzyme PAM is a critical component of the regulated secretory pathway in beta cells, consistent with the observed effects of PAM missense variants on T2D risk and insulinogenic index. Our results establish molecular mechanisms for T2D-associated PAM risk alleles, and reveal multiple effects of reduced PAM function on insulin granule packaging and release from beta cells, potentially via amidation of CgA. Our study illustrates the importance of coding variants implicated in disease risk to the identification of causal genes for mechanistic studies. Further work is required to explore the possible contribution of other tissues to PAM function, particularly those that reveal implications for incretin-based therapies.
MATERIALS AND METHODS
Cloning of PAM expression plasmids
A pCMV6 expression vector encoding integral membrane H. sapiens PAM (NM_138821.2)
with an in-frame C-terminal Myc-Flag tag (PAM-Myc-Flag) was purchased from Origene.
Soluble functional PAM-Myc-Flag encompassing the first 710 amino acids was generated via PCR using primers 5'GTACCCAGAATGTAGCTCC3' and 
Cell culture and transfection
Human islets were freshly isolated at the Oxford Centre for Islet Transplantation (OXCIT) in
Oxford, UK, as described (49) 
Kinetic analysis of variant PAM substrate affinity
For K m calculations, a 12-point two-fold serial dilution of hippuric acid in which the maximum concentration was 20mM was prepared in assay mix (100mM MES pH 5.5, 2µM
CuSO 4 , 10mM L-ascorbic acid, 0.1mg/mL bovine liver catalase). Recombinant PAM or empty vector control supernatant was then added. The amount of D563G-PAM added to the assay was increased such that it displayed equal V max to WT-PAM. The volume of empty vector supernatant matched the volume of WT-PAM used in that experiment. Vials were incubated in a 37°C water bath for 1hr. Samples were then removed into a conical 96-well plate containing 40mM EDTA pH 8.0.
Gene expression analyses
Gene expression was measured via Taqman were normalised to the combined average of the housekeeping genes PPIA and TBP. PAM expression in human islets and sorted beta cells and non-beta cells was analysed based on previously published RNA sequencing data (20) .
Immunofluorescent labelling and microscopy
For light microscopy, analyses were performed on 4μm sections. Human pancreatic specimens fixed in 10% formalin and embedded in wax were used to localise PAM in islets. 
Insulin secretion and membrane capacitance assays in EndoC-βH1
Insulin secretion assays were performed as previously described (51) . The CyQUANT Direct
Cell Proliferation Assay (Thermo Fisher) was used to count cells according to manufacturer's instructions. Insulin secretion and content measurements were normalised to cell count on a per-well basis to account for differences in the number of plated cells. Corrected values were then normalised to basal insulin secretion rates for scrambled on a per-experiment basis to eliminate variability in baseline secretion rates across biological replicates.
Electrophysiological measurements were performed using an EPC10 Patch Clamp Amplifier (HEKA) at 32°C using the standard whole cell configuration as previously described (52) . Tetraethylammonium chloride (20mM) was added to block residual K + currents.
Electron microscopy
Transfected EndoC-βH1 cells were fixed in 2.5% glutaraldehyde, post-fixed in 2% uranyl acetate, dehydrated in graded methanol, and embedded in London Resin Gold (Agar Scientific). Ultrathin sections cut onto nickel grids were immunolabelled for PAM (Abcam ab109175) followed by anti-rabbit biotin (Vector Laboratories) and streptavidin gold 15nm (Biocell). Insulin was immunolabelled using an in-house antibody followed by anti-guinea pig gold 10nm (Biocell). Sections were viewed on a Joel 1010 microscope (accelerating voltage 80kV) with a digital camera (Gatan). To estimate PAM concentration in secretory vesicles, semi-automatic quantification of immunogold labelling was performed by a blinded observer using Image J software. The following parameters were determined: cross-sectional vesicle area, vesicle density (number of vesicles/cytoplasmic area), and insulin or PAM labelling/vesicle (number of immunogold particles/vesicle).
Western blot analysis of CgA amidation
Whole-cell extracts (WCE) from siRNA or inhibitor-treated EndoC-βH1 cells were prepared as previously described (53) . Supernatant was harvested directly from cells and filtered with a 0.22μm filter. Protein yields were determined by the Bio-Rad Protein Assay according to manufacturer's instructions. We routinely analysed 2-10μg WCE and 0.5% total supernatant volume via denaturing SDS-PAGE. Antibodies specific for CgA-Gly (Abcam ab52983) (34) and total CgA (Abcam ab15160) were used to calculate the ratio of amidated to non-amidated CgA using Image Lab 5.0.
Analysis of exocytosis in primary human beta cells
Human pancreatic islets were isolated and prepared at the Alberta Diabetes Institute IsletCore as previously described (54) . Single-cell capacitance responses were monitored as described above, with an additional pre-incubation period of 1 hour at 1 mM glucose. Following recordings, cells were positively identified by insulin immunostaining and islet samples were genotyped as previously described (50 hoc test was applied to detect statistically significant differences.
Statistics
All statistical analyses were performed in R v3.0.2, except electron microscopy data and electrophysiological measurements in EndoC-βH1 cells, which were analysed using OriginPro v8.5.1. Graphs show means of the indicated number of replicates, and error bars are SEM. For kinetic data, rates were found to be dependent on substrate concentration, and exponential models were fitted. Kinetic and cellular assay data were analysed using twosided Welch's t-test; electrophysiological, electron microscopy, and Western data using paired student's t-test. 
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